United Kingdom· GB-APID-42762411000001108
Takhzyro 150mg/1ml solution for injection pre-filled syringes
A lanadelumab product containing lanadelumab, registered in United Kingdom by Takeda UK Ltd. The same ATC class is registered in 15 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Lanadelumab is registered in 15 of 19 countries.
Countries holding a registration under ATC B06AC05 (lanadelumab), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 10 of them publish a price we can compare per daily dose
Lanadelumab · ATC B06AC05
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of lanadelumab costs, country by country.
Normalised to the WHO defined daily dose (21.4 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Lanadelumab · price per daily dose (21.4 mg)
USD · FX 28 Sept 2026
- CH Switzerland$857.11
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Lanadelumab
- Manufacturer
- Takeda UK Ltd
- Country
- United Kingdom (GB)
- ATC code
- B06AC05
- ATC class
- Lanadelumab
- Defined daily dose
- 21.4 mg, P
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 2
- gtin07038319163966
- gtin7038319163966
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Lanadelumab in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaTAKHZYROTakeda Pharmaceuticals International AG Ireland Branch, Dublin
- SpainTAKHZYRO 150 MG SOLUCION INYECTABLE EN JERINGA PRECARGADATakeda Pharmaceuticals International Ag Ireland Branch
- IcelandTakhzyroTakeda Pharmaceuticals International AG Ireland Branch
- NorwayTakhzyroTakeda Pharmaceuticals International AG Ireland Branch
- PolandTakhzyroTakeda Pharmaceuticals International AG
- BelgiumTakhzyro 150 mgTakeda Pharmaceuticals International Ireland Branch
- SwedenTAKHZYRO 150 mg Injektionsvätska, lösning i förfylld sprutaTakeda Pharmaceuticals International AG Ireland Branch
- SwitzerlandTAKHZYRO 150 mg, Injektionslösung in einer FertigspritzeTakeda Pharma AG
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Takhzyro
- Liechtenstein · Takhzyro
- Norway · Takhzyro
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/57ae8e12-6f54-4668-bbdd-797d4770e0d0 GET /v1/drugs/57ae8e12-6f54-4668-bbdd-797d4770e0d0?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "42762411000001108",
"desc": "Takhzyro 150mg/1ml solution for injection pre-filled syringes (Takeda UK Ltd)",
"form": "Solution for injection",
"vpid": "42769011000001106",
"source": "dmd",
"vtm_id": "776471003",
"strength": "150 mg",
"substance": "Lanadelumab",
"ingredient": "Lanadelumab",
"supplier_code": "3811601000001107"
}See everything about lanadelumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.